EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...

BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

Those earning up to Rs 12 lakh annually won't have to pay any income tax under the new regime. Add to it the standard deduction of Rs 75,000 and taxpayers with up to Rs 12.75 lakh annual income ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to ...

The 2024 End-of-Year Report showcases significant changes in the tax landscape, indicating additional complexity in 2025 KING OF PRUSSIA, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vertex Inc.

Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today released the findings of their 2024 U.S. state ...